文献速递前列腺增生与排尿功能障碍

前列腺动脉栓塞治疗非索引良性前列腺增生患者的尿潴留和前列腺源性肉眼血尿:单中心结局

Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria.
PubMed 文献 · Urology · 2019-11-14

结果显示PAE可安全、有效且持久地解除尿潴留并控制血尿,3个月时87%尿潴留患者拔除尿管,92%血尿患者在随访期间无血尿复发。

要点

  • PAE后3个月87%尿潴留患者拔除尿管,36个月时仍达83%。
  • PAE后92%血尿患者长期无血尿复发,严重血尿者输血需求显著减少。
  • PAE相关不良事件以Clavien-Dindo II级尿路感染为主(11%)。

核心结论

  • PAE为因尿潴留和/或前列腺源性肉眼血尿的非索引良性前列腺增生患者提供了安全、有效且持久的治疗。

研究设计与样本

  • 尿潴留组46例(留置尿管162.4±148.1天),肉眼血尿组55例,其中26例同时存在两种问题。

主要发现

  • PAE后3个月33/38(87%)尿潴留患者拔除尿管,IPSS 8.9±5.3,QoL 1.6±1.7,PVR 158±207 mL;6、12、24、36个月拔管率分别为93%、95%、92%、83%。
  • 肉眼血尿组37例中34例(92%)在483±137天随访期内无血尿复发,PAE前血尿相关就诊22次,PAE后无就诊。
  • 严重血尿需膀胱冲洗组16例中14例(87.5%)血尿在PAE后48小时内缓解;PAE前输血36单位,PAE后48小时内输血4单位,此后无输血。
  • 严重血尿组随访500±501天,13/16(81%)无血尿复发,2/16(13%)需电灼治疗,1/16(6%)发现膀胱肿瘤。
  • PAE后30天内死亡2例,8例(11%)发生Clavien-Dindo II级尿路感染。

关键数值与推荐

  • 尿潴留患者PAE后1-2个月进行排尿试验,并在3、6、12、24、36个月记录IPSS、QoL和PVR。
  • 肉眼血尿患者比较PAE前后血尿相关就诊次数;严重血尿需膀胱冲洗患者比较输血率。

临床怎么用

  • 对于因尿潴留或前列腺源性肉眼血尿不适合常规手术的非索引良性前列腺增生患者,PAE可作为安全有效的治疗选择。
  • PAE可显著减少血尿相关就诊和输血需求,多数严重血尿在48小时内缓解。
  • 需注意PAE后尿路感染等Clavien-Dindo II级不良事件,并监测罕见膀胱肿瘤发生。

局限性

  • 尿潴留和血尿亚组分析中部分时间点数据缺失(如3个月拔管率仅38例可评估)。
  • 缺乏对照组,无法直接比较PAE与其他治疗方式的优劣。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present outcomes for prostatic artery embolization (PAE) to treat urinary retention and gross prostatic hematuria in nonindex benign prostatic hyperplasia patients. MATERIALS AND METHODS: Seventy-five patients undergoing PAE from December 2013 to August 2018 (age = 77.5 ± 8.6, age-adjusted Charlson comorbidity index = 4.6 ± 2.0, prostate volume = 224 mL ± 135 mL) for retention (n = 46) and/or gross prostatic hematuria (n = 55) were retrospectively reviewed. Twenty-six patients had both problems. Urinary retention patients (UR, n = 46, catheterization = 162.4 ± 148.1 days) underwent voiding trials 1-2 months post-PAE, with International Prostate Symptom Score (IPSS), Quality of Life (QoL), and postvoid residual (PVR) recorded at 3, 6, 12, 24, and 36 months. Pre- and post-PAE hematuria-related visits were compared for gross hematuria patients (GH, n = 39), as were transfusion rates for severe hematuria patients requiring bladder irrigation (SH, n = 16). Ninety-day adverse event tabulation used Clavien-Dindo classification. RESULTS: Three months post-PAE, 33/38(87%) UR patients were catheter-free (IPSS = 8.9 ± 5.3, QoL = 1.6 ± 1.7, PVR = 158 mL ± 207 mL). Results were similar at 6 months (catheter-free = 26/28(93%), IPSS = 6.5 ± 4.4, QoL = 1.1 ± 0.9, PVR = 149 mL ± 139 mL), 12 months (catheter-free = 19/20(95%), IPSS = 4.7 ± 4.8, QoL = 0.6 ± 0.9, PVR = 125 mL ± 176 mL), 24 months (catheter-free = 11/12(92%), IPSS = 4.4 ± 3.0, QoL = 0.9 ± 0.8, PVR = 66 mL ± 68 mL), and 36 months (catheter-free = 5/6(83%), IPSS = 5.8 ± 3.8, QoL = 0.8 ± 1.0, PVR =99 mL ± 71 mL). Out of 37, 34(92%) GH patients remained hematuria-free at 483 ± 137 days, with 22 hematuria-related visits pre-PAE vs none post-PAE. Hematuria resolved <48 hours post-PAE in 14/16(87.5%) SH patients, with 36 blood units transfused pre-PAE, 4 units transfused <48 hours post-PAE, and none thereafter. Subsequently, 13/16(81%) remained hematuria-free at 500 ± 501 days; 2/16(13%) required fulguration; 1/16(6%) developed bladder tumor. There were 2 deaths <30 days post-PAE, and 8(11%) Grade-II urinary infections. CONCLUSION: PAE provided safe, effective, and durable treatment for retention and gross hematuria in nonindex benign prostatic hyperplasia patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ayyagari R, Powell T, Staib L, et al. Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. Urology. 2019. PMID: 31734349. doi:10.1016/j.urology.2019.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。